-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shp2 can be described as an emerging star anti-cancer drug target in recent years.
Shp2 drugs that inhibit Shp2 can attack cancer cells in a different way than other therapies, providing cancer patients with new hope
https://doi.
Experimental schematic diagram Even though previous studies have shown that the loss of Shp2 can inhibit tumor development, Myc-driven carcinogenesis in Shp2-deficient livers can also lead to rapid tumor deterioration, which shows the contradictory role of Shp2 in cancer
The scRNA-seq test design inhibits Shp2, which induces an unexpectedly complex immunosuppressive environment in the liver , which interferes with the clearance of tumor-initiating cells in the early stages of the disease and aggravates tumor progression in the later stages
Part of the SHP2 inhibitor pipeline (picture source: Shenghui compiled according to public information) ICP-189 lung cancer of Nuocheng Jianhua, Yituo Pharmaceutical, Gacus, Betta Pharmaceuticals, Shenghe Pharmaceutical, Qinhao Pharmaceutical Nuocheng Jianhua Digest the SHP2 allosteric inhibitor ET0038 developed by FDA Yituo Pharmaceutical, the SHP2 inhibitor SH3809 independently developed by Shenghe Pharmaceutical, and the management plus Kesi Pharmaceutical JAB-3068 and JAB-3312
Leave a comment here
Shp2 drugs that inhibit Shp2 can attack cancer cells in a different way than other therapies, providing cancer patients with new hope
https://doi.
Experimental schematic diagram Even though previous studies have shown that the loss of Shp2 can inhibit tumor development, Myc-driven carcinogenesis in Shp2-deficient livers can also lead to rapid tumor deterioration, which shows the contradictory role of Shp2 in cancer
The scRNA-seq test design inhibits Shp2, which induces an unexpectedly complex immunosuppressive environment in the liver , which interferes with the clearance of tumor-initiating cells in the early stages of the disease and aggravates tumor progression in the later stages
Part of the SHP2 inhibitor pipeline (picture source: Shenghui compiled according to public information) ICP-189 lung cancer of Nuocheng Jianhua, Yituo Pharmaceutical, Gacus, Betta Pharmaceuticals, Shenghe Pharmaceutical, Qinhao Pharmaceutical Nuocheng Jianhua Digest the SHP2 allosteric inhibitor ET0038 developed by FDA Yituo Pharmaceutical, the SHP2 inhibitor SH3809 independently developed by Shenghe Pharmaceutical, and the management plus Kesi Pharmaceutical JAB-3068 and JAB-3312
Reference materials:
[1] [2] [3] [4] [5] [6] [7]Leave a comment here
